Protagonist therapeutics, inc. (PTGX)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss

-83,164

-77,187

-73,551

-65,877

-45,366

-38,924

-28,111

-24,201

-30,517

-36,957

0

0

0

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation

8,422

8,353

8,265

8,081

7,713

6,919

6,036

5,226

4,583

4,241

4,572

3,813

2,917

2,130

0

0

0

Operating lease right-of-use asset amortization

1,777

1,792

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

790

703

629

585

579

527

516

473

396

406

364

339

332

317

0

0

0

Amortization of debt issuance costs and accretion of debt discount

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of discount on marketable securities, net of premium amortization

664

594

495

113

8

-206

-494

-525

-685

-687

-532

-317

-157

-117

0

0

0

Foreign currency remeasurement loss

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in deferred tax asset

-772

-775

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value associated with redeemable convertible preferred stock tranche liability

-

-

-

-

-

-

-

-

-

-

-

-

-

4,194

0

0

0

Change in fair value of redeemable convertible preferred stock warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

525

0

0

0

Changes in operating assets and liabilities:
Research and development tax incentive receivable

0

-

-

-

71

236

364

-586

-566

-1,070

0

0

0

-

-

-

-

Research and development tax incentive receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Receivable from collaboration partner - related party

-1,467

2,168

-2,641

-895

2,339

2,771

0

0

0

-

-

-

-

-

-

-

-

Prepaid expenses and other assets

1,608

2,820

995

1,494

439

-1,117

841

1,224

769

333

587

1,240

1,161

1,804

0

0

0

Accounts payable

-2,783

-3,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-

-

-

-

-

-

-

-

263

-

824

1,228

-859

-115

0

0

0

Payable to collaboration partner - related party

-95

201

256

534

832

1,061

0

0

0

-

-

-

-

-

-

-

-

Accrued expenses and other payables

3,451

1,098

-116

-2,392

-2,116

1,911

2,768

7,260

4,408

4,793

5,461

4,710

4,137

3,395

0

0

0

Deferred revenue - related party

32,044

33,307

30,708

28,365

-14,879

-23,529

0

0

0

-

-

-

-

-

-

-

-

Operating lease liability

1,899

1,885

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-40,713

-41,527

-37,373

-32,403

-51,471

-49,947

-53,961

-3,981

-910

3,872

0

0

0

-

-

-

-

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of marketable securities

166,093

166,936

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of available-for-sale securities

-

-

-

-

-

-

-

-

57,180

-

94,927

74,775

81,171

73,169

0

0

0

Proceeds from maturities of marketable securities

151,944

114,193

101,124

91,124

95,759

73,759

66,235

62,805

53,235

56,035

42,335

26,665

13,590

14,188

0

0

0

Net cash provided by (used in) operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Purchases of property and equipment

939

967

811

1,268

444

486

480

522

826

666

662

488

144

347

0

0

0

Net cash provided by investing activities

-15,088

-53,710

-36,607

5,349

28,165

2,213

2,416

-8,273

-4,771

15,823

0

0

0

-

-

-

-

CASH FLOWS FROM FINANCING ACTIVITIES
Issuance costs related to issuance of long-term debt

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock upon exercise of stock options and purchases under employee stock purchase plan

1,795

1,779

1,767

807

794

934

1,150

1,150

1,163

1,007

0

0

0

-

-

-

-

Proceeds from issuance of common stock upon exercise of stock options and purchases under employee stock purchase plan

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Net cash provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

22,508

0

0

0

Net cash provided by financing activities

46,045

46,036

36,736

34,531

23,975

24,115

88,698

65,697

65,710

65,554

0

0

0

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Effect of exchange rate changes on cash, cash equivalents and restricted cash

-106

-26

0

0

0

-

-

-

-

146

0

0

0

-

-

-

-

Net increase (decrease) in cash, cash equivalents and restricted cash

-9,862

-49,227

-37,232

7,279

500

-23,796

37,032

53,499

60,060

85,395

0

0

0

-

-

-

-

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Effect of exchange rate changes on cash and cash equivalents

-106

-26

0

0

0

-

-

-

-

146

94

101

102

22

0

0

0

Net (decrease) increase in cash and cash equivalents

-9,862

-49,227

-37,232

7,279

500

-23,796

37,032

53,499

60,060

85,395

-45,179

-2,953

-18,662

17,029

0

0

0

SUPPLEMENTAL DISCLOSURES OF NON-CASH FINANCING AND INVESTING INFORMATION:
Purchases of property and equipment in accounts payable and accrued liabilities

-544

100

0

0

0

-

-

0

0

-

27

63

139

21

0

0

0

Accretion of redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Deferred offering costs in accounts payable and accrued liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Tenant improvement allowance reimbursement

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Settlement of fair value of redeemable convertible preferred stock liability

-

-

-

-

-

-

-

-

-

-

-

-

-

5,837

0

0

0